Can Pfizer get Xeljanz, Xtandi pumping while it waits for pipeline help?

30th April 2019 Uncategorised 0

X marks the spot for Pfizer—that is, the spots where its products are struggling to live up to expectations. Analysts pointed to weaker-than-expected showings from both anti-inflammatory drug Xeljanz and cancer-fighter Xtandi in the first quarter.

More: Can Pfizer get Xeljanz, Xtandi pumping while it waits for pipeline help?
Source: fierce